Last $5.74 USD
Change Today -0.33 / -5.44%
Volume 64.7K
ATNM On Other Exchanges
Symbol
Exchange
NYSE Amex
Frankfurt
As of 5:15 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).

actinium pharmaceuticals inc (ATNM) Snapshot

Open
$6.08
Previous Close
$6.07
Day High
$6.30
Day Low
$5.74
52 Week High
04/3/14 - $15.00
52 Week Low
12/19/13 - $4.50
Market Cap
172.2M
Average Volume 10 Days
74.1K
EPS TTM
$-1.05
Shares Outstanding
30.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINIUM PHARMACEUTICALS INC (ATNM)

Related News

No related news articles were found.

actinium pharmaceuticals inc (ATNM) Related Businessweek News

No Related Businessweek News Found

actinium pharmaceuticals inc (ATNM) Details

Actinium Pharmaceuticals, Inc., a biotechnology company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy (APIT) platform. Its products include Bismab-A for acute myeloid leukemia; Actimab-A, an antibody-drug construct that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia; and Iomab-B, an antibody-drug construct used in myeloconditioning for hematopoietic stem cells transplantation in various indications. The company was formerly known as Cactus Ventures, Inc. and changed its name to Actinium Pharmaceuticals, Inc. in April 2013. Actinium Pharmaceuticals, Inc. was founded in 2000 and is based in New York, New York.

6 Employees
Last Reported Date: 03/19/14
Founded in 2000

actinium pharmaceuticals inc (ATNM) Top Compensated Officers

Chief Executive Officer, President, Interim C...
Total Annual Compensation: $112.1K
Chief Operating Officer and Chief Medical Off...
Total Annual Compensation: $295.5K
Compensation as of Fiscal Year 2013.

actinium pharmaceuticals inc (ATNM) Key Developments

Actinium Pharmaceuticals, Inc. Announces Positive Interim Data from the Ongoing Phase I/II trial of Actimab-A

Actinium Pharmaceuticals, Inc. announced positive interim data from the ongoing Phase I/II trial of Actimab-A in older patients with newly diagnosed Acute Myeloid Leukemia (AML). Most notably, median overall survival ("OS") of the seven secondary AML patients (with prior myelodysplastic syndrome, or MDS) in the study was 9.1 months, which is a prolongation of life compared to historical norms of typically 2 to 5 months. Older AML patients are already higher risk, with secondary AML patients considered to have the more severe and less treatable form of AML, and the shortest expected survival. The clinical abstract will be published and available online in Blood, the official Journal of the American Society of Hematology.

Actinium Announces Collaboration with Albert Einstein College of Medicine on New Actinium Program

Actinium Pharmaceuticals, Inc. announced collaboration with Albert Einstein College of Medicine on New Actinium Program. The company and Albert Einstein College of Medicine of Yeshiva University started development of an antibody construct labeled with actinium-225 using a novel technology that potentially allows for the expansion of use of the Company's proprietary platform and enables further manufacturing improvements of alpha therapy technology based drug candidates. The first antibody to be labeled using the new technology has potential to be broadly used in the field of hematology/oncology. Preclinical studies of the new technology have demonstrated significant improvements in product's manufacturing while maintaining biological integrity and properties of labeled antibodies. In addition to making the manufacturing process more time and cost efficient, the new technology allows for a greater versatility in adjusting the final constructs to various clinical situations. Clinical trials of drug candidates based on alpha emitting isotopes have already demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery.

Actinium Pharmaceuticals, Inc. - Special Call

To discuss on emerging therapies for Acute Myeloid Leukemia

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATNM:US $5.74 USD -0.33

ATNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ATNM.
View Industry Companies
 

Industry Analysis

ATNM

Industry Average

Valuation ATNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 75.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINIUM PHARMACEUTICALS INC, please visit www.actiniumpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.